Listed
2025-09
First close
KRW 5631.75
split-adjusted
Since listing
+3700%
23 points—
Current
KRW 214000.00
≈ $36.7 B · 2026-11-13 KST
Peak
KRW 215000.00
≈ $36.8 B2026-11
Low
KRW 179800.00
≈ $30.8 B2026-10
Latest change
+2.1%
2026-11-12 → 2026-11-13
Change since first
+19.0%
2026-10
52-week range
KRW 158500.00 – KRW 239047.63
Drawdown
-10.5%
Avg vol 3m
506K
Dividend yield
0.33%
Price history
Oct 14, 2026 – Nov 13, 2026
Monthly closes from Yahoo Finance, split-adjusted, dividends excluded. Earlier points are actual closes, not reconstructed.
DateCloseMarket capChange
- 11-13KRW 214000.00$36.7 B+2.1%
- 11-12KRW 209500.00$35.9 B+1.2%
- 11-11KRW 207000.00$35.5 B+2.0%
- 11-10KRW 203000.00$34.8 B-3.3%
- 11-09KRW 210000.00$36 B-0.5%
- 11-06KRW 211000.00$36.1 B-1.9%
- 11-05KRW 215000.00$36.8 B+7.5%
- 11-04KRW 200000.00$34.3 B+5.3%
- 11-03KRW 189900.00$32.5 B-1.1%
- 11-02KRW 192000.00$32.9 B+0.2%
- 10-30KRW 191600.00$32.8 B+1.2%
- 10-29KRW 189300.00$32.4 B-0.3%
- 10-28KRW 189800.00$32.5 B+0.6%
- 10-27KRW 188600.00$32.3 B-0.7%
- 10-26KRW 190000.00$32.6 B-2.3%
- 10-23KRW 194400.00$33.3 B+0.1%
- 10-22KRW 194300.00$33.3 B-1.7%
- 10-21KRW 197600.00$33.9 B+0.1%
- 10-20KRW 197400.00$33.8 B-0.4%
- 10-19KRW 198200.00$34 B+2.2%
- 10-16KRW 194000.00$33.2 B+6.5%
- 10-15KRW 182100.00$31.2 B+1.3%
- 10-14KRW 179800.00$30.8 B—
Ownership & Control
Shareholding as of 2026-11-06- Controlling entity
- Celltrion Holdings Co., Ltd. — 21.80%
- Insiders
- —
- Institutions
- —
- Free float
- —
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →- Celltrion to Present New Analyses of ZYMFENTRA (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 20262026-10-12
- Celltrion Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn on Record Quarterly Revenue and Cost Improvements2026-07-27
- Celltrion Announces U.S. Commercial Availability of AVTOZMA (tocilizumab-anoh) Subcutaneous Formulation2026-03-16
